In this context, Pentraxin 3 (PTX3)—an acute-phase protein produced by myeloid and endothelial cells—has emerged as a potential biomarker of inflammatory activity, endothelial dysfunction, and disease prognosis [12,13,14,15]. This evidence concerns the gene PTX3 and endothelial dysfunction.